{"id":"anti-tnf-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Increased infection risk (including tuberculosis)"},{"rate":"10-20","effect":"Injection site reactions"},{"rate":"15-25","effect":"Upper respiratory tract infections"},{"rate":"10-15","effect":"Headache"},{"rate":null,"effect":"Malignancy risk (long-term)"},{"rate":null,"effect":"Demyelinating disease"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TNF is a pro-inflammatory cytokine produced by immune cells that promotes inflammation and tissue damage in autoimmune and inflammatory diseases. By neutralizing TNF through monoclonal antibodies or receptor antagonists, anti-TNF therapy suppresses excessive inflammatory responses. This reduces symptoms and prevents progression in conditions like rheumatoid arthritis, inflammatory bowel disease, and psoriasis.","oneSentence":"Anti-TNF therapy blocks tumor necrosis factor (TNF), a key inflammatory cytokine that drives immune-mediated inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:27:28.642Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Inflammatory bowel disease (Crohn's disease and ulcerative colitis)"},{"name":"Psoriasis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Juvenile idiopathic arthritis"}]},"trialDetails":[{"nctId":"NCT06654882","phase":"PHASE3","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-09","conditions":"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)","enrollment":400},{"nctId":"NCT07234838","phase":"","title":"Effect of Anti-Psoriatic Biologics on Risk of Anogenital Warts (CONDYPSO)","status":"RECRUITING","sponsor":"Jonathan Krygier","startDate":"2026-02-01","conditions":"Psoriasis, Condyloma Acuminata, Biotherapies","enrollment":600},{"nctId":"NCT04870203","phase":"PHASE3","title":"Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2021-07-15","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT07475065","phase":"PHASE2, PHASE3","title":"The Effect of Oral DLBS1033 in Patients With Diabetic Polyneuropathy","status":"NOT_YET_RECRUITING","sponsor":"Universitas Sebelas Maret","startDate":"2026-03-01","conditions":"Diabetic Polyneuropathy, Peripheral Nervous System Diseases, Peripheral Neuropathy","enrollment":34},{"nctId":"NCT06812988","phase":"PHASE2","title":"Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-28","conditions":"Type 1 Diabetes Mellitus","enrollment":84},{"nctId":"NCT00606346","phase":"","title":"A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Biotech, Inc.","startDate":"2007-05-31","conditions":"Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis","enrollment":4970},{"nctId":"NCT05960578","phase":"PHASE2","title":"Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Washington","startDate":"2024-05-23","conditions":"Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8","enrollment":8},{"nctId":"NCT03646708","phase":"","title":"Response Assessment in SB CD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2018-05-09","conditions":"Small Bowel Crohn's Disease","enrollment":112},{"nctId":"NCT07453628","phase":"","title":"Association of Erectile Dysfunction With Neuropathic Pain, Disease Activity, and Functional Status in Male Patients With Axial Spondyloarthritis: A Cross-Sectional Observational Study","status":"COMPLETED","sponsor":"Altuğ Güner","startDate":"2021-02-03","conditions":"Ankylosing Spondylitis, Sexual Dysfunction","enrollment":90},{"nctId":"NCT00385086","phase":"PHASE3","title":"Lumbar Spinal Fibrosis and TNF Alpha Inhibition","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2007-02","conditions":"Post Operative Sciatica by Lumbar Spinal Fibrosis","enrollment":38},{"nctId":"NCT05889182","phase":"PHASE3","title":"A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-06-21","conditions":"Hidradenitis Suppurativa","enrollment":1328},{"nctId":"NCT07441239","phase":"","title":"Patient-Reported Sleep vs Objective Sleep and Physical Activity Measures in Ankylosing Spondylitis: A Pre-Post Study","status":"COMPLETED","sponsor":"Samsun University","startDate":"2015-08-01","conditions":"Ankylosing Spondylitis (AS), Sleep Quality, Physical Activity","enrollment":18},{"nctId":"NCT06728930","phase":"","title":"Evaluation of a Novel Microbiological Diagnostic Test for Latent Mycobacterium Tuberculosis Infection","status":"ENROLLING_BY_INVITATION","sponsor":"Queen Mary University of London","startDate":"2024-04-02","conditions":"Latent Tuberculosis Infection, Tuberculosis Infection, Latent","enrollment":250},{"nctId":"NCT07280702","phase":"PHASE4","title":"Deucravacitinib-TNF Combination Therapy for Difficult-to-Control Psoriatic Disease","status":"NOT_YET_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-04-15","conditions":"Psoriatic Arthritis (PsA)","enrollment":128},{"nctId":"NCT06227026","phase":"PHASE1","title":"Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CAR-T Cells) for the Treatment of Relapsed/Refractory CD19+ Malignancies","status":"RECRUITING","sponsor":"University of Utah","startDate":"2024-02-20","conditions":"Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma","enrollment":10},{"nctId":"NCT05139602","phase":"PHASE2","title":"A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2021-12-28","conditions":"Hidradenitis Suppurativa","enrollment":210},{"nctId":"NCT06301477","phase":"NA","title":"PRecisiOn Microbiome Directed ExtensiOn of Anti-TNFα Crohn's Disease ThErapy in Children: The PROMOTE Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Eastern Ontario","startDate":"2024-12-01","conditions":"Inflammatory Bowel Diseases, Crohn Disease","enrollment":45},{"nctId":"NCT06896305","phase":"NA","title":"Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study","status":"RECRUITING","sponsor":"IRCCS Ospedale San Raffaele","startDate":"2025-05-22","conditions":"Ulcerative Colitis (UC), Crohn Disease (CD)","enrollment":80},{"nctId":"NCT01000441","phase":"PHASE4","title":"Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2009-12-23","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT07349472","phase":"PHASE2","title":"Pentoxifylline in Patients With Ulcerative Colitis","status":"NOT_YET_RECRUITING","sponsor":"Ihab Elsayed Hassan","startDate":"2026-01-20","conditions":"Inflammatory Bowel Diseases","enrollment":60},{"nctId":"NCT07344428","phase":"NA","title":"Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease: A Randomized Trial","status":"NOT_YET_RECRUITING","sponsor":"Sixth Affiliated Hospital, Sun Yat-sen University","startDate":"2026-02-01","conditions":"Crohn's Disease；Mucosal Healing；Dietary Intervention","enrollment":185},{"nctId":"NCT07314606","phase":"NA","title":"Combining Nutritional Therapy and Anti-TNFα Treatment in Pediatric Patients With Crohn's Disease","status":"NOT_YET_RECRUITING","sponsor":"University of British Columbia","startDate":"2025-12-15","conditions":"Crohn Disease (CD), IBD (Inflammatory Bowel Disease), IBD - Inflammatory Bowel Disease","enrollment":140},{"nctId":"NCT01022749","phase":"PHASE3","title":"Efficacy Safety Study of Flu Vaccine in Immunodepression Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-09","conditions":"Inflammatory Bowel Disease (IBD)","enrollment":228},{"nctId":"NCT07229469","phase":"NA","title":"A Study on Sumac Mouth Rinse for Treating Recurrent Aphthous Stomatitis","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-12-20","conditions":"Recurrent Aphthous Stomatitis","enrollment":38},{"nctId":"NCT04374877","phase":"PHASE1","title":"Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Coherus Oncology, Inc.","startDate":"2020-04-22","conditions":"Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma","enrollment":145},{"nctId":"NCT05271318","phase":"PHASE1, PHASE2","title":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.","status":"RECRUITING","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2022-05-17","conditions":"Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma","enrollment":29},{"nctId":"NCT05379322","phase":"PHASE3","title":"The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients","status":"WITHDRAWN","sponsor":"Abu Dhabi Stem Cells Center","startDate":"2023-03-01","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT05428488","phase":"PHASE3","title":"Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2022-11-28","conditions":"Rheumatoid Arthritis","enrollment":220},{"nctId":"NCT02508012","phase":"NA","title":"Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2015-09-24","conditions":"Crohn's Disease, Ulcerative Colitis","enrollment":260},{"nctId":"NCT04899154","phase":"NA","title":"Analysis of Intestinal Microbiota as a Predictor of Response to Treatment of Spondyloarthritis With Biotherapy","status":"RECRUITING","sponsor":"Hôpital Européen Marseille","startDate":"2019-07-16","conditions":"Spondyloarthritis","enrollment":80},{"nctId":"NCT05781152","phase":"PHASE4","title":"Clinical, Imaging, and Endoscopic Outcomes of Children Newly Diagnosed With Crohn's Disease","status":"RECRUITING","sponsor":"Connecticut Children's Medical Center","startDate":"2023-06-10","conditions":"Crohn Disease","enrollment":900},{"nctId":"NCT06925061","phase":"PHASE2","title":"Target Engagement of EXL01 in the Prevention of Post-operative Recurrence of Crohn's Disease","status":"RECRUITING","sponsor":"Madeleine Bezault","startDate":"2025-03-31","conditions":"Crohn Disease (CD)","enrollment":80},{"nctId":"NCT01394276","phase":"","title":"An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":322},{"nctId":"NCT01385826","phase":"PHASE2, PHASE3","title":"Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2011-06-29","conditions":"Uveitis, Juvenile Arthritis","enrollment":34},{"nctId":"NCT06545812","phase":"NA","title":"Immune Response During the Conservative and Minimal Invasive Treatment of Pain Caused by Lumbar Disc Herniation","status":"RECRUITING","sponsor":"Josip Juraj Strossmayer University of Osijek","startDate":"2024-09-02","conditions":"Intervertebral Disc Herniation, Back Pain, Analgesic Nephropathy","enrollment":128},{"nctId":"NCT07152977","phase":"","title":"Description of the Radiological Response of Anoperineal Fistulizing Lesions of Crohn's Disease","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2019-07-31","conditions":"Anoperineal Lesions, Crohn's Disease Relapse","enrollment":52},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT04524611","phase":"PHASE3","title":"Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-09-30","conditions":"Crohn's Disease (CD)","enrollment":527},{"nctId":"NCT04997733","phase":"PHASE3","title":"Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF Withdrawal","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-22","conditions":"Crohn Disease","enrollment":150},{"nctId":"NCT04985435","phase":"PHASE4","title":"Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)","status":"RECRUITING","sponsor":"R.Bos","startDate":"2021-05-12","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT05222932","phase":"PHASE1","title":"Oncolytic Adenovirus TILT-123 and Avelumab for Treatment of Solid Tumors Refractory to or Progressing After Anti-PD(L)1","status":"ACTIVE_NOT_RECRUITING","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2023-03-08","conditions":"Melanoma, Head and Neck Squamous Cell Carcinoma","enrollment":15},{"nctId":"NCT06418529","phase":"","title":"A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-05-15","conditions":"Rheumatoid Arthritis","enrollment":21340},{"nctId":"NCT03915964","phase":"PHASE4","title":"A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-25","conditions":"Rheumatoid Arthritis","enrollment":2663},{"nctId":"NCT03358693","phase":"","title":"Molecular Signatures in Inflammatory Skin Disease","status":"RECRUITING","sponsor":"Prof. Dr. Stephan Weidinger","startDate":"2017-01-20","conditions":"Atopic Dermatitis, Psoriasis","enrollment":300},{"nctId":"NCT04086745","phase":"PHASE4","title":"A Study of Baricitinib in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-14","conditions":"Rheumatoid Arthritis","enrollment":1317},{"nctId":"NCT04817072","phase":"NA","title":"Evaluation of Mood Disorders Under Biologics in Chronic Inflammatory Rheumatic Disease","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2021-05-19","conditions":"Rheumatic Diseases, Mood Disorders","enrollment":108},{"nctId":"NCT07041112","phase":"","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","status":"COMPLETED","sponsor":"Juan Ruano Ruiz","startDate":"2012-01-01","conditions":"Psoriasis, Psoriatic Arthritis (PsA), Cardiovascular Risk Factors","enrollment":1000},{"nctId":"NCT01081717","phase":"","title":"Golimumab Safety and Surveillance Program Using the Ingenix NHI Database","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2009-04-14","conditions":"Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing Spondylitis","enrollment":1064},{"nctId":"NCT01081730","phase":"","title":"Ustekinumab Safety and Surveillance Program Using the Ingenix NHI Database","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2010-02-09","conditions":"Psoriasis","enrollment":2040},{"nctId":"NCT02713997","phase":"PHASE4","title":"Anti-inflammatory Therapy to Improve Outcomes After TPIAT","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2016-12","conditions":"Pancreatitis, Chronic; Diabetes; Transplant","enrollment":43},{"nctId":"NCT03679546","phase":"PHASE4","title":"EFFICACI : EFFicacy of Intravenous Infliximab Versus Vedolizumab After Failure of subCutaneous Anti-TNF in Patients With UlCerative Colitis","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2019-01-04","conditions":"Ulcerative Colitis","enrollment":151},{"nctId":"NCT03847467","phase":"PHASE1, PHASE2","title":"Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy","status":"RECRUITING","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2019-09-20","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","enrollment":116},{"nctId":"NCT04504136","phase":"NA","title":"Regulation of Mucosal Healing in Inflammatory Bowel Disease","status":"RECRUITING","sponsor":"Terrence A Barrett","startDate":"2021-04-30","conditions":"Inflammatory Bowel Diseases","enrollment":60},{"nctId":"NCT02711202","phase":"NA","title":"Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2007-01","conditions":"Kidney Transplantation","enrollment":20},{"nctId":"NCT03011268","phase":"NA","title":"Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?","status":"COMPLETED","sponsor":"Helse Møre og Romsdal HF","startDate":"2017-06-09","conditions":"Colitis,Ulcerative","enrollment":174},{"nctId":"NCT05040464","phase":"PHASE3","title":"Comparison of Azathioprine to Methotrexate in Combination Therapy With Adalimumab in Crohn's Disease: an Open-label Randomized Controlled Trial","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2021-08-26","conditions":"Crohn Disease, Azathioprine, Methotrexate","enrollment":166},{"nctId":"NCT03765450","phase":"","title":"Pharmacokinetics of IFX and TNF Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimentiv Inc.","startDate":"2018-12-21","conditions":"Ulcerative Colitis","enrollment":18},{"nctId":"NCT05080218","phase":"PHASE4","title":"COVID-19 VaccinE Response in Rheumatology Patients","status":"COMPLETED","sponsor":"Jeffrey Curtis","startDate":"2021-11-15","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis","enrollment":841},{"nctId":"NCT02438787","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-07-31","conditions":"Axial Spondyloarthritis","enrollment":315},{"nctId":"NCT02437162","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2015-09-03","conditions":"Axial Spondyloarthritis","enrollment":347},{"nctId":"NCT04571697","phase":"","title":"A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-28","conditions":"Dementia, Alzheimer Disease","enrollment":34647},{"nctId":"NCT04655807","phase":"PHASE2","title":"A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease","status":"WITHDRAWN","sponsor":"Janssen Research & Development, LLC","startDate":"2021-03-03","conditions":"Crohn Disease","enrollment":""},{"nctId":"NCT06818045","phase":"NA","title":"Nonsurgical Periodontal Treatment Combined With Anti-TNF-α in Patients With Rheumatoid Arthritis and Periodontitis","status":"COMPLETED","sponsor":"Hatice Yemenoğlu","startDate":"2024-03-01","conditions":"Peridontal Disease, Rheumatic Arthritis","enrollment":46},{"nctId":"NCT06918886","phase":"","title":"Comparison of Liver Health in Psoriatic Arthritis Patients Using Anti-TNF or Anti-IL17 Treatments","status":"NOT_YET_RECRUITING","sponsor":"Bezmialem Vakif University","startDate":"2025-04-10","conditions":"Psoriatic Arthritis (PsA), Liver Fibrosis, Liver Diseases","enrollment":90},{"nctId":"NCT05599347","phase":"PHASE2","title":"Pre-treatment With Azithromycin to Reduce Immunogenicity to to Anti-TNF Agents in Patients With Crohn's Disease","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2023-04-24","conditions":"Crohn's Disease Relapse, Biological Substance; Adverse Effect","enrollment":180},{"nctId":"NCT06281106","phase":"PHASE2, PHASE3","title":"TYK2 Inhibition in Paradoxical Psoriasis","status":"TERMINATED","sponsor":"Prof Curdin Conrad","startDate":"2024-06-20","conditions":"Psoriasis","enrollment":2},{"nctId":"NCT06653634","phase":"PHASE4","title":"Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-10-24","conditions":"Juvenile Idiopathic Arthritis","enrollment":150},{"nctId":"NCT05197530","phase":"PHASE1","title":"Imaging of Lymphatic Vessels in People with Rheumatoid Arthritis (RA)","status":"RECRUITING","sponsor":"University of Rochester","startDate":"2021-12-30","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT03885713","phase":"PHASE4","title":"Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"Fundación de Investigación Biomédica - Hospital Universitario de La Princesa","startDate":"2019-09-10","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis","enrollment":180},{"nctId":"NCT06089590","phase":"","title":"Ibd CAncer and seRious Infections in France (I-CARE 2)","status":"RECRUITING","sponsor":"Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives","startDate":"2024-01-25","conditions":"IBD, Ulcerative Colitis, Crohn Disease","enrollment":6000},{"nctId":"NCT05552105","phase":"NA","title":"The Oxylipin Response as a New PrEdictive Biomarker of Patient Responsiveness to Biotherapy in Rheumatoid Arthritis (OPERA)","status":"COMPLETED","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2022-09-27","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT06213857","phase":"PHASE2","title":"Beneficial Effect of Silymarin in Ulcerative Colitis","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-02-01","conditions":"Ulcerative Colitis","enrollment":44},{"nctId":"NCT03397108","phase":"","title":"Assessing the Drug Exposure Risk of Infants Breastfed by Women With Inflammatory Bowel Disease","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2017-08-31","conditions":"Crohn's Disease, Ulcerative Colitis, Healthy Controls","enrollment":79},{"nctId":"NCT04505410","phase":"PHASE3","title":"Second Line Induction Therapy and Healthy Diet for Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"University of Miami","startDate":"2020-09-18","conditions":"Ulcerative Colitis","enrollment":32},{"nctId":"NCT03591770","phase":"PHASE4","title":"Shingrix Vaccine in Patients With Moderate to Severe Ulcerative Colitis on Tofacitinib","status":"TERMINATED","sponsor":"Boston Medical Center","startDate":"2019-07-31","conditions":"Inflammatory Bowel Diseases","enrollment":15},{"nctId":"NCT05703932","phase":"NA","title":"Examining the Effect of Home-Based Exercise on Disease Activity in Patients With Ankylosing Spondylitis Using SIRI and SII","status":"COMPLETED","sponsor":"Bakirkoy Dr. Sadi Konuk Research and Training Hospital","startDate":"2023-02-01","conditions":"Ankylosing Spondylitis","enrollment":64},{"nctId":"NCT00658827","phase":"","title":"Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and Psoriasis","status":"COMPLETED","sponsor":"Janssen Biotech, Inc.","startDate":"2007-01-01","conditions":"Inflammatory Bowel Disease","enrollment":370},{"nctId":"NCT03796858","phase":"PHASE3","title":"A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy","status":"COMPLETED","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2019-03-22","conditions":"Arthritis, Psoriatic","enrollment":285},{"nctId":"NCT05299242","phase":"PHASE2, PHASE3","title":"The Anti-Freaze-F Study- \"Anti-TNF for Treatment of Frozen Shoulder - a Feasibility Study\"","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2022-07-21","conditions":"Frozen Shoulder","enrollment":9},{"nctId":"NCT05090124","phase":"NA","title":"Experimental Medicine Studies of the Brain in Patients With Rheumatoid Arthritis REALISE","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2022-11-04","conditions":"Rheumatoid Arthritis","enrollment":46},{"nctId":"NCT06514092","phase":"","title":"Study on the Long-Term Risk of Recurrence of Anoperineal Fistula in Crohn's Disease","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2024-09-17","conditions":"Crohn Disease","enrollment":81},{"nctId":"NCT04646187","phase":"PHASE4","title":"De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease","status":"ENROLLING_BY_INVITATION","sponsor":"University Medical Center Groningen","startDate":"2021-03-11","conditions":"Inflammatory Bowel Diseases, Crohn Disease, Colitis, Ulcerative","enrollment":148},{"nctId":"NCT04118556","phase":"PHASE2","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","status":"RECRUITING","sponsor":"Mats Remberger","startDate":"2021-12-01","conditions":"GVHD, Acute","enrollment":50},{"nctId":"NCT03629379","phase":"PHASE4","title":"Response to Ustekinumab for Anti-tnf Induced Psoriasiform Skin Lesions","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-01-22","conditions":"Inflammatory Bowel Diseases, Psoriasis","enrollment":20},{"nctId":"NCT02557308","phase":"","title":"An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Ankylosing Spondylitis","status":"TERMINATED","sponsor":"Celltrion","startDate":"2015-05-26","conditions":"Ankylosing Spondylitis","enrollment":329},{"nctId":"NCT01706692","phase":"","title":"Swiss Dermatology Network of Targeted Therapies (SDNTT)","status":"RECRUITING","sponsor":"Swiss Dermatology Network for Targeted Therapies","startDate":"2011-02","conditions":"Psoriasis","enrollment":1121},{"nctId":"NCT02610569","phase":"NA","title":"Comparison of PillCamCOLON (C2) Capsule and Standard Endoscopy for the Evaluation of Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Dr. Arnaud Bourreille","startDate":"2014-04","conditions":"Ulcerative Colitis","enrollment":50},{"nctId":"NCT02557295","phase":"","title":"An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With RA","status":"TERMINATED","sponsor":"Celltrion","startDate":"2013-12-17","conditions":"Rheumatoid Arthritis","enrollment":248},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT06642207","phase":"","title":"Effect of IL17 Inhibitor in Comparison With Anti-TNF in Patients With Ankylosing Spondylitis","status":"RECRUITING","sponsor":"Sohag University","startDate":"2024-10-01","conditions":"Ankylosing Spondylitis","enrollment":50},{"nctId":"NCT06269185","phase":"","title":"Comparison Between Infliximab and Adalimumab on Patients With Ulcerative Colitis","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2024-03-06","conditions":"Ulcerative Colitis, Inflammatory Bowel Diseases","enrollment":271},{"nctId":"NCT04301128","phase":"NA","title":"The Effect of Mobile Application on Subcutaneous Anti-TNF Drug Administration:Ankylosing Spondylitis Patients","status":"COMPLETED","sponsor":"Eskisehir Osmangazi University","startDate":"2017-12-27","conditions":"Ankylosing Spondylitis, Spondylitis, Ankylosing","enrollment":32},{"nctId":"NCT04061161","phase":"PHASE4","title":"Anti-inflammatory Effects of Tiotropium in Patients with Stable COPD","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2019-08-19","conditions":"COPD","enrollment":37},{"nctId":"NCT06603337","phase":"","title":"Sequencing in Inflammatory Bowel Diseases (IBD) Therapy: \"the Latium Net\".","status":"RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2024-09-18","conditions":"IBD (Inflammatory Bowel Disease)","enrollment":2700},{"nctId":"NCT05788510","phase":"","title":"Pneumococcal Vaccination in Patients with Anti-TNF Alpha Therapy","status":"COMPLETED","sponsor":"Hôpital NOVO","startDate":"2023-04-03","conditions":"Pneumococcal Vaccine","enrollment":106},{"nctId":"NCT06601595","phase":"","title":"Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital","status":"NOT_YET_RECRUITING","sponsor":"Mohamed Nasr","startDate":"2024-10","conditions":"Inflammatory Bowel Disease (IBD), Spondylarthropathies, TNF-alpha Inhibitors","enrollment":100},{"nctId":"NCT04485325","phase":"PHASE4","title":"Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients","status":"COMPLETED","sponsor":"Dr. Frank Behrens","startDate":"2019-11-04","conditions":"Rheumatic Arthritis","enrollment":92},{"nctId":"NCT06563635","phase":"","title":"Frequency of Tuberculosis in Psoriasis Patients","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2023-05-01","conditions":"Psoriasis Vulgaris, Tuberculosis","enrollment":719},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT03182426","phase":"PHASE1, PHASE2","title":"Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2017-08-15","conditions":"Diabetes Mellitus, Type 1","enrollment":22}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2738,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Remicade, Inflectra, Renflexis, Avsola, Humira, Amgevita, Hulio, Hadlima, Hyrimoz, Idacio"],"phase":"marketed","status":"active","brandName":"Anti-TNF Therapy","genericName":"Anti-TNF Therapy","companyName":"Takeda","companyId":"takeda","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anti-TNF therapy blocks tumor necrosis factor (TNF), a key inflammatory cytokine that drives immune-mediated inflammation. Used for Rheumatoid arthritis, Inflammatory bowel disease (Crohn's disease and ulcerative colitis), Psoriasis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}